Sunshine Biopharma Inc (SBFM)

[EOT]

DD on just what we have here. I’m comparing the #1 cancer treatment used today....
ETOPOSIDE compared to Adva-27a...
CHECK THIS OUT!!!!


ETOPOSIDE...

https://www.apexbt.com/etoposide.html

Background
Etoposide (VP-16) is the first agent recognized as a topoisomerase II inhibitor of anticancer drug with IC50 of 59.2 µM.

That’s..... 59.2







http://www.sunshinebiopharma.com/assets/press/Pr_Rel_TopoII_Inhibition_at_red_V3_Final.pdf

SBFM initial 2011 studies state WE are at 13.7..



“An IC50 of 13.7 micromolar indicates that Adva-27a is an excellent inhibitor of Topoisomerase II”, said Dr. Steve N. Slilaty, Sunshine’s President and CEO. “Compounds displaying IC50’s in the 75 to 100 micromolar range cannot be developed into effective drugs as the amounts which would have to be administered to patients would be too toxic. We are delighted to find that our compound has such low IC50. This is a significant milestone in our continued development of Adva-27a”, he added.



https://www.sunshinebiopharma.org/anticancer-research

WOW....now down to 1.44

Adva-27a is an excellent inhibitor of Topoisomerase II
with an IC50 of only 13.7 micromolar (this number has recently been reduce
to 1.44 micromolar as a result of resolving the two isomeric forms
of Adva-27a).



I believe this was the key that triggered the beginning of clinical trials last month

Feb 2019...
http://www.sunshinebiopharma.com/assets/press/Press_Release_Notice_of_Allownace_20190204_V3_Final.pdf

The new patent (US Patent Application Number 20150353573) contains new subject matter





I believe that the 16x more effective than ETOPOSIDE.....
has likely increased dramatically!!